Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cbd seizures:

Search results

Items: 1 to 20 of 97

1.

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C.

Epilepsia. 2019 Feb 11. doi: 10.1111/epi.14670. [Epub ahead of print]

PMID:
30740695
2.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM.

J Clin Pharmacol. 2019 Feb 7. doi: 10.1002/jcph.1387. [Epub ahead of print] Review.

PMID:
30730563
3.

A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety.

Steele G, Arneson T, Zylla D.

Curr Oncol Rep. 2019 Feb 1;21(1):10. doi: 10.1007/s11912-019-0757-7. Review.

PMID:
30707319
4.

US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions.

Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M.

Front Vet Sci. 2019 Jan 10;5:338. doi: 10.3389/fvets.2018.00338. eCollection 2018.

5.

Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex.

Serra I, Scheldeman C, Bazelot M, Whalley BJ, Dallas ML, de Witte PAM, Williams CM.

Behav Brain Res. 2019 Jan 23;363:135-144. doi: 10.1016/j.bbr.2019.01.040. [Epub ahead of print]

PMID:
30684511
6.

Preclinical safety and efficacy of cannabidivarin for early life seizures.

Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA.

Neuropharmacology. 2019 Jan 10;148:189-198. doi: 10.1016/j.neuropharm.2019.01.002. [Epub ahead of print]

PMID:
30633929
7.

Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Chen JW, Borgelt LM, Blackmer AB.

Ann Pharmacother. 2019 Jan 8:1060028018822124. doi: 10.1177/1060028018822124. [Epub ahead of print]

PMID:
30616356
8.

Plants come to mind: phytocannabinoids, endocannabinoids and the control of seizures.

Farrell JS, Soltesz I.

Addiction. 2018 Dec 27. doi: 10.1111/add.14540. [Epub ahead of print] No abstract available.

PMID:
30589476
9.

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models.

Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ.

Epilepsia. 2019 Feb;60(2):303-314. doi: 10.1111/epi.14629. Epub 2018 Dec 26.

PMID:
30588604
10.

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.

Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C.

Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018 Dec 23.

PMID:
30582156
11.

Cannaboinoid Antiemetic Therapy.

Taylor BN, Sauls RS.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Dec 21.

12.

Simultaneous quantification of thirteen cannabinoids and metabolites in human plasma by liquid chromatography tandem mass spectrometry in adult epilepsy patients.

Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK.

Ther Drug Monit. 2018 Dec 4. doi: 10.1097/FTD.0000000000000583. [Epub ahead of print]

PMID:
30520828
13.

Emerging drugs for the treatment of Dravet syndrome.

Brigo F, Striano P, Balagura G, Belcastro V.

Expert Opin Emerg Drugs. 2018 Nov 27. doi: 10.1080/14728214.2018.1552937. [Epub ahead of print]

PMID:
30482063
14.

Epilepsy and Cannabis: A Literature Review.

Zaheer S, Kumar D, Khan MT, Giyanwani PR, Kiran F.

Cureus. 2018 Sep 10;10(9):e3278. doi: 10.7759/cureus.3278. Review.

15.

Efficacy of cannabinoids in paediatric epilepsy.

Ali S, Scheffer IE, Sadleir LG.

Dev Med Child Neurol. 2019 Jan;61(1):13-18. doi: 10.1111/dmcn.14087. Epub 2018 Nov 6. Review.

PMID:
30402932
16.

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.

Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M.

Drugs. 2018 Nov;78(17):1791-1804. doi: 10.1007/s40265-018-0992-5. Review.

PMID:
30390221
17.

Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells.

Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, Holzmann K, Lavorgna M, Isidori M, Knasmüller S.

Arch Toxicol. 2019 Jan;93(1):179-188. doi: 10.1007/s00204-018-2322-9. Epub 2018 Oct 19.

18.

Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.

Pamplona FA, da Silva LR, Coan AC.

Front Neurol. 2018 Sep 12;9:759. doi: 10.3389/fneur.2018.00759. eCollection 2018. Erratum in: Front Neurol. 2019 Jan 10;9:1050.

19.

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome.

McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead OC 3rd.

Ann Clin Transl Neurol. 2018 Aug 1;5(9):1077-1088. doi: 10.1002/acn3.621. eCollection 2018 Sep.

20.

Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.

Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P.

Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2.

Supplemental Content

Loading ...
Support Center